Crossmark

Exploratory biomarker analysis from a phase III study of the PI3K inhibitor, copanlisib, in combination with rituximab in patients with indolent non-Hodgkin lymphoma, a retrospective study

Crossref DOI link: https://doi.org/10.1007/s12094-025-03869-2

Published Online: 2025-02-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chaturvedi, Shalini https://orcid.org/0009-0003-3261-6539
Weispfenning, Anke

Descamps, Tine

Bellinvia, Sara

Bauer, David

Du, Rong

Lunt, Teresa

Soler, Lidia Mongay

Childs, Barrett H.

Zinzani, Pier Luigi
Funding

Funding for this research was provided by:

Bayer Corporation
License Information

Text and Data Mining valid from 2025-02-21

Version of Record valid from 2025-02-21
More Information

Article History

Received: 20 November 2024

Accepted: 4 February 2025

First Online: 21 February 2025

Declarations

:

: S. Chaturvedi, L. Mongay Soler, B.H. Childs, and R. Du are employees of Bayer HealthCare Pharmaceuticals, Inc. A. Weispfenning and D. Bauer are employees of Bayer AG. T. Descamps is an employee of Bayer plc. S. Bellinvia is an employee of Chrestos Concept, a contract partner of Bayer. T. Lunt is an employee of Belcan. P.L. Zinzani discloses: consulting for MSD, EUSA Pharma, and Novartis; speaker bureau involvement with Celltrion, Gilead, Janssen-Cilag, Bristol Myers Squibb, Servier, MSD, AstraZeneca, Takeda, Roche, EUSA Pharma, Kyowa Kirin, Novartis, Incyte, and BeiGene; and advisory board participation with Secura Bio, Celltrion, Gilead, Janssen-Cilag, Bristol Myers Squibb, Servier, Sandoz, MSD, AstraZeneca, Takeda, Roche, EUSA Pharma, Kyowa Kirin, Novartis, ADC Therapeutics, Incyte, and BeiGene.

: The study protocol was approved by each study site's independent ethics committee or institutional review board and was done in accordance with the updated Declaration of Helsinki.

: All patients signed the written informed consent they were provided.

Document is current

Any future updates will be listed below